Antimicrobial Resistance and Multidrug-Resistant Bacteria in Infectious Patients, 2nd Edition

Dear Colleagues,

This Special Issue is a continuation of our 2024 Special Issue titled "Antimicrobial Resistance and Multidrug-Resistant Bacteria in Infectious Patients".

Welcome to this Special Issue of Microorganisms, titled “Antimicrobial Resistance and Multidrug-Resistant Bacteria in Infectious Patients, 2nd Edition”.

Antimicrobial resistance is considered a worldwide burden, affecting the patients of critical hospital wards, such as intensive care units (ICUs). Hospitalized patients have been demonstrated to have an increased risk of developing infections due to exposure to several invasive devices (mechanical ventilation, urinary tract catheters) and to other related conditions. Careful clinical surveillance, together with the monitoring of the well-known bacterial strains responsible for inducing HAI, may help clinicians to choose the appropriate antibiotic therapy.

Bacterial infections have always impacted humans, and were particularly harmful until the discovery of antibiotics, which revolutionized the treatment of infectious diseases. Because of their ability to survive in different environments, bacteria are increasingly able to face antibacterial treatments over time by means of different adaptative strategies. They can modify the quaternary structure of specific target proteins, substitute metabolic pathways by synthesizing alternative biomolecules, and produce enzymes capable of inactivating antibiotics; this is also possible through their camouflaged structure, for example, behind a proteoglycan capsule.

A common bacterial weapon against penicillin is the beta-lactamase enzyme, which alters the beta-lactamic structure, thus maintaining the stability of the bacterial wall and creating the local conditions needed to promote several diseases. Bacteria are also able to synthesize effective isoforms of the beta-lactamase enzyme; extended-spectrum beta lactamase (ESBL) and ESBL carbapenemase give bacteria resistance to third-generation cephalosporins and carbapenamase-class antibiotics, respectively. These antibiotics are widely used in several nosocomial infections.

Recently, several strategies have been proposed to face this challenge, such as strong prevention or the support of computer-based analyses. The EU’s call for projects has also promoted the development of innovative artificial intelligence (AI) solutions to prevent infections inside clinical departments. In particular, an interesting ongoing project (LAOCOONTE, by Energent S.p.A.) has the objective of developing specific use cases, where data can be used by machine- and deep-learning models to evaluate the likelihood of infection in clinical departments, in an Italian clinical setting. This approach is very promising; in fact, AI currently plays an important role in different fields, from smart manufacturing to the internet of things, human–computer interaction, and medicine.

The attention paid by the scientific community and industry to the field of AI is related to the excellent performance achieved in recent years by so-called artificial neural networks, and in particular deep architectures, in various fields such as text, images, and audio.

Nosocomial infections (NIs) are even more preventable, as they represent a biological and social cost for hospitalized patients. The growing availability of computerized patient records in hospitals allows for the improvement of data storage with traditional machine-learning methods, which have been shown to outperform deep learning’s performance when applied to tabular data.

Additionally, nanoparticles associated with antibiotics are used as an effective therapeutic method to combat multi-drug-resistant bacteria, and gold nanoparticles are used against viruses such as HIV and Ebola.

Prof. Dr. Danila De Vito
Dr. Patrizia Nardulli
Dr. Maria Rita Laforgia
Dr. Antonio Parisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• diffusion multi-drug resistant bacteria
• outbreak by ESKAPE bacteria
• hospital infections
• care-related infections
• anti-microbial nano-particles
• role of antimicrobial nanomaterials in medicine
• mechanism of action of antimicrobial nanomaterials
• antimicrobial food packaging